‌

US Patent 11759527 Anti-EGFR antibody-drug conjugates

Patent 11759527 was granted and assigned to AbbVie Inc. on September, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Andrew C. Phillips

Erwin R. Boghaert

John E. Harlan

Kamel Izeradjene

Andrew J. Souers

Date of Patent

September 19, 2023

Patent Application Number

17580134

Date Filed

January 20, 2022

Patent Citations

US Patent 7507716 Method for treating pain with prolactin antagonists

US Patent 7521541 Cysteine engineered antibodies and conjugates

US Patent 7589180 Specific binding proteins and uses thereof

US Patent 7598028 Compositions and methods for detecting and treating prostate disorders

US Patent 7612181 Dual variable domain immunoglobulin and uses thereof

US Patent 7723270 Methods for producing members of specific binding pairs

US Patent 7741319 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines

US Patent 7223837 Elongated and multiple spacers in activatible prodrugs

...

Patent Primary Examiner

Vanessa L. Ford

CPC Code

Patent abstract

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11759527 Anti-EGFR antibody-drug conjugates

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.